Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- M00073 - Provider product page
- Provider
- Boster Biological Technology
- Product name
- Anti-FoxO1a Rabbit Monoclonal Antibody
- Antibody type
- Monoclonal
- Description
- Monoclonal antibody for FKHR/FOXO1 detection. Host: Rabbit.Size: 100ug/vial. Tested applications: IF, IHC, ICC, WB. Reactive species: Human, Mouse, Rat FKHR/FOXO1 information: Molecular Weight: 69662 MW; Subcellular Localization: Cytoplasm . Nucleus . Shuttles between the cytoplasm and nucleus. Largely nuclear in unstimulated cells. In osteoblasts, colocalizes with ATF4 and RUNX2 in the nucleus (By similarity). Insulin-induced phosphorylation at Ser-256 by PKB/AKT1 leads, via stimulation of Thr-24 phosphorylation, to binding of 14-3-3 proteins and nuclear export to the cytoplasm where it is degraded by the ubiquitin-proteosomal pathway. Phosphorylation at Ser-249 by CDK1 disrupts binding of 14-3-3 proteins and promotes nuclear accumulation. Phosphorylation by NLK results in nuclear export. Translocates to the nucleus upon oxidative stress-induced phosphorylation at Ser-212 by STK4/MST1. SGK1-mediated phosphorylation also results in nuclear translocation. Retained in the nucleus under stress stimuli including oxidative stress, nutrient deprivation or nitric oxide. Retained in the nucleus on methylation; Tissue Specificity: Ubiquitous.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Antibody clone number
- CIA-6
- Vial size
- 100ug/vial
- Concentration
- 0.5-1mg/ml, actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.
- Storage
- At -20°C for one year. Avoid repeated freezing and thawing.
Submitted references Research and experimental verification of the molecular mechanism of berberine in improving premature ovarian failure based on network pharmacology.
Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway.
FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake.
Xue W, Xue F, Jia T, Hao A
Bioengineered 2022 Apr;13(4):9885-9900
Bioengineered 2022 Apr;13(4):9885-9900
Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway.
Zhang Y, Li C, Li X, Wu C, Zhou H, Lu S, Liu X
Molecular medicine reports 2020 Sep;22(3):2174-2182
Molecular medicine reports 2020 Sep;22(3):2174-2182
FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake.
Li L, Zhao H, Chen B, Fan Z, Li N, Yue J, Ye Q
Journal of translational medicine 2019 Dec 13;17(1):418
Journal of translational medicine 2019 Dec 13;17(1):418
No comments: Submit comment
Supportive validation
- Submitted by
- Boster Biological Technology (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of paraffin-embedded human brain carcinoma, using FoxO1a Antibody(M00073)FOXO1 was detected in paraffin-embedded tissue section. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1ug/ml rabbit anti-FOXO1 Antibody (M00073)overnight at 4
- Additional image
